Invesco Portfolio holdings
Invesco Ltd., founded in 1978 and headquartered in Atlanta, Georgia, is a global investment management firm managing hundreds of billions in assets across a diverse range of products, including mutual funds, exchange-traded funds (ETFs), and institutional portfolios. Known for its blend of active and passive investment strategies, Invesco serves individual investors, financial advisors, and institutions, with a strong presence in North America, Europe, and Asia, bolstered by acquisitions like OppenheimerFunds in 2019. The firm offers specialized solutions in equities, fixed income, real estate, and alternatives, leveraging its global research capabilities to cater to varying market needs. Invesco’s commitment to innovation and client-focused investing has solidified its reputation as a versatile player in the asset management industry.
Top Buys
| 1 |
Texas Instruments
TXN
|
$638M |
| 2 |
Broadcom
AVGO
|
$602M |
| 3 |
Tesla
TSLA
|
$492M |
| 4 |
American International
AIG
|
$465M |
| 5 |
Advanced Micro Devices
AMD
|
$421M |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$426M |
| 2 |
Pinduoduo
PDD
|
$393M |
| 3 |
DexCom
DXCM
|
$367M |
| 4 |
Synopsys
SNPS
|
$350M |
| 5 |
Manhattan Associates
MANH
|
$290M |
Sector Composition
| 1 | Technology | 23.41% |
| 2 | Financials | 12.14% |
| 3 | Industrials | 11.35% |
| 4 | Healthcare | 11.18% |
| 5 | Consumer Discretionary | 10.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSTX
3551
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $109K | ﹤0.01% |
32,386
+4,722
| +17% | +$15.9K |
|
3552
Cullinan Oncology
CGEM
$408M
| $108K | ﹤0.01% |
+10,623
| New | +$108K |
|
3553
Zevra Therapeutics
ZVRA
$501M
| $108K | ﹤0.01% |
16,504
+3,133
| +23% | +$20.5K |
|
3554
Inspired Entertainment
INSE
$250M
| $107K | ﹤0.01% |
10,831
-25,114
| -70% | -$248K |
|
3555
NextDecade
NEXT
$2.74B
| $104K | ﹤0.01% |
21,907
+5,641
| +35% | +$26.9K |
|
3556
Vivid Seats
SEAT
$99.9M
| $103K | ﹤0.01% |
812
+163
| +25% | +$20.6K |
|
3557
Organogenesis Holdings
ORGO
$638M
| $102K | ﹤0.01% |
24,863
+2,791
| +13% | +$11.4K |
|
|
CBH
3558
DELISTED
Virtus Convertible & Income 2024 Target Term Fund
CBH
| $101K | ﹤0.01% |
11,619
+8
| +0.1% | +$70 |
|
3559
Copel
ELP
$6.65B
| $101K | ﹤0.01% |
11,943
-29,255
| -71% | -$248K |
|
3560
Shengfeng Development Ltd
SFWL
$85.8M
| $101K | ﹤0.01% |
34,239
-3,829
| -10% | -$11.3K |
|
3561
Nano X Imaging
NNOX
$238M
| $100K | ﹤0.01% |
15,766
+3,275
| +26% | +$20.9K |
|
3562
Purple Innovation
PRPL
$119M
| $99.5K | ﹤0.01% |
96,579
-8,473
| -8% | -$8.73K |
|
|
KG
3563
Kestrel Group, Ltd.
KG
$201M
| $99.1K | ﹤0.01% |
2,164
+414
| +24% | +$19K |
|
3564
Annexon
ANNX
$236M
| $98.8K | ﹤0.01% |
21,772
+3,281
| +18% | +$14.9K |
|
|
ENFN
3565
DELISTED
Enfusion, Inc.
ENFN
| $98.3K | ﹤0.01% |
10,131
-2,116
| -17% | -$20.5K |
|
3566
Castor Maritime
CTRM
$19.6M
| $98K | ﹤0.01% |
23,060
+259
| +1% | +$1.1K |
|
3567
Heron Therapeutics
HRTX
$202M
| $97.4K | ﹤0.01% |
57,312
-1,383
| -2% | -$2.35K |
|
3568
Ovid Therapeutics
OVID
$91.7M
| $96.2K | ﹤0.01% |
29,885
+6,898
| +30% | +$22.2K |
|
|
BPT
3569
DELISTED
BP Prudhoe Bay Royalty Trust
BPT
| $94.1K | ﹤0.01% |
38,107
+408
| +1% | +$1.01K |
|
|
NIU
3570
Niu Technologies
NIU
$335M
| $93.9K | ﹤0.01% |
42,895
-4,806
| -10% | -$10.5K |
|
3571
Lexicon Pharmaceuticals
LXRX
$389M
| $93.6K | ﹤0.01% |
61,182
+9,245
| +18% | +$14.1K |
|
3572
American Express Global Business Travel
GBTG
$3.9B
| $92.1K | ﹤0.01% |
14,278
-2,200
| -13% | -$14.2K |
|
3573
PDS Biotechnology
PDSB
$56.9M
| $90.7K | ﹤0.01% |
18,249
-1,667
| -8% | -$8.29K |
|
3574
Y-mAbs Therapeutics
YMAB
$389M
| $90.4K | ﹤0.01% |
13,261
+1,477
| +13% | +$10.1K |
|
3575
Mural Oncology
MURA
$35.9M
| $88.8K | ﹤0.01% |
+15,002
| New | +$88.8K |
|